The global inhaled nitric oxide market size was valued at USD 1034.21 million in 2025 and is projected to grow from USD 1121.08 million in 2026 to USD 2137.33 million by 2034, registering a CAGR of 8.4% during the forecast period from 2026 to 2034. North America dominated the inhaled nitric oxide market with a market share of 42.6% in 2025.
Inhaled nitric oxide is a pulmonary vasodilator that regulates vascular muscle tone significantly. It has emerged as a treatment for hypoxemic respiratory failure in newborns with persistently high pulmonary vascular pressure and resulting right-to-left blood shunting (persistent pulmonary hypertension of the newborn).
For example, around 2% of all live births and over 33% of newborn mortality occur annually owing to neonatal hypoxia respiratory failure (HRF). In contrast, 0.4-6.8/1000 live birth years are affected by persistent pulmonary hypertension of the newborn (PPHN). The mortality rate for those with moderate to severe forms of the illness remains around 10%. Neonatal hypoxic respiratory failure is characterized by persistent pulmonary hypertension of the infant and various disorders that contribute to pulmonary arterial hypertension, such as meconium aspiration syndrome, sepsis, birth asphyxia, and respiratory distress syndrome.
Nitric oxide is a selective pulmonary vasodilator administered to the patient by mechanical ventilation following dilution with an oxygen/air mixture nitric oxide delivery device. 100 ppm and 800 ppm quantities of nitric oxide are available depending on the therapy. In addition, clinical trials explore using inhaled nitric oxide for several diseases. The potential therapeutic effect of this in adults is still unknown, and indications approved by the FDA are limited to pediatric practice.
Download a Free Sample To learn more about this report,
Shift Toward Tankless and Point-of-Care Nitric Oxide Systems
Hospitals are increasingly moving from high-pressure nitric oxide cylinders toward compact systems that generate or store gas at the point of care. These platforms reduce cylinder handling, storage needs, delivery delays, and administrative work while supporting treatment during transfers between neonatal intensive care, operating rooms, and other hospital departments. Built-in monitoring of nitric oxide, oxygen, and nitrogen dioxide also improves workflow and treatment control. Competition is therefore shifting from gas supply alone toward portable devices, integrated safety features, technical support, and flexible hospital contracts. This transition is encouraging established suppliers and newer manufacturers to invest in cylinder-free technologies.
Growing Need for Rapid Respiratory Support in Critical Care
Demand is supported by the need to improve oxygenation in term and near-term newborns with hypoxic respiratory failure linked to pulmonary hypertension. Inhaled nitric oxide selectively relaxes pulmonary blood vessels and can reduce the need for extracorporeal membrane oxygenation when used with ventilatory support. Rising awareness of neonatal respiratory complications, stronger neonatal intensive-care capacity, and broader access to advanced ventilation systems are increasing treatment availability. Respiratory disease also creates research interest beyond neonatal care, including COPD and acute respiratory distress syndrome. The CDC reports that nearly 16 million U.S. adults have COPD, underlining the large respiratory-care burden that encourages further clinical investigation.
Limited Approved Uses and High Treatment Costs
Market expansion is restricted by the therapy’s narrow approved indication, specialized delivery requirements, and substantial hospital costs. In the United States, approved products primarily treat hypoxic respiratory failure associated with pulmonary hypertension in term and near-term newborns. Adult use remains largely off-label or investigational, limiting routine reimbursement and adoption. Treatment also requires calibrated equipment, continuous gas monitoring, trained respiratory professionals, backup delivery arrangements, and careful dose reduction. These requirements make adoption harder for smaller hospitals and facilities in lower-income regions. Price competition from newer delivery systems is also putting pressure on established brands and changing hospital purchasing decisions.
Expansion of Portable Systems and New Clinical Applications
Major opportunities are emerging from cylinder-free delivery, geographic expansion, and research into additional respiratory conditions. Systems that generate nitric oxide from room air can reduce dependence on cylinder transport, storage, replacement, and complex supply arrangements. This could improve access in smaller hospitals, emergency settings, and regions with weak medical-gas infrastructure. Manufacturers can also pursue growth through distributor partnerships, hospital purchasing agreements, and devices suitable for transport between care departments. Longer-term opportunities exist in viral pneumonia, COPD, pulmonary hypertension, and acute respiratory distress syndrome, although these applications require strong clinical evidence and regulatory clearance before broad commercialization.
Maintaining Safety, Consistent Dosing, and Clinical Evidence
Inhaled nitric oxide must be delivered accurately because treatment errors can quickly affect critically ill patients. Nitrogen dioxide may form when nitric oxide mixes with oxygen, potentially causing airway inflammation and lung injury. Higher exposure can also raise methemoglobin levels and reduce the blood’s oxygen-carrying capacity. Abrupt withdrawal may worsen oxygenation and trigger rebound pulmonary hypertension, making controlled weaning essential. Suppliers must therefore provide dependable monitoring, backup delivery, equipment maintenance, clinician training, and uninterrupted service. Another challenge is demonstrating meaningful long-term outcomes beyond temporary oxygenation improvement, especially for adult and off-label applications where evidence remains mixed and regulatory approval is limited.
The neonatal respiratory treatment segment dominated the Inhaled Nitric Oxide Market with a 64.8% market share, valued at USD 0.67 billion, and recorded a CAGR of 7.63%. Its leading position reflects the specialized use of inhaled nitric oxide in neonatal intensive care, where selective pulmonary vasodilation helps support oxygen exchange in newborns with serious pulmonary circulation-related respiratory conditions.
Request Customizationto receive a tailored report.
The Inhaled Nitric Oxide Gas segment represents a major product category in the Inhaled Nitric Oxide Market because the gaseous formulation allows controlled administration through specialized delivery systems in hospital settings. Its established use is supported by the need for precise dosing, continuous monitoring, and compatibility with respiratory support equipment during supervised treatment. Market share, market value, and CAGR figures are not included because numerical data were not provided.
Speak to an Analystto discuss market opportunities.
North America holds the largest share of the global inhaled nitric oxide market at 42.6%, valued at USD 0.44 billion in 2025, and is projected to grow at 7.45% CAGR through the forecast period. The region's dominance stems from well-established neonatal intensive care infrastructure, high awareness of pulmonary hypertension treatments, and favorable reimbursement policies for advanced respiratory therapies.
The United States dominates the inhaled nitric oxide market, driven by high prevalence of respiratory conditions in newborns and established healthcare infrastructure. Stringent FDA regulations around pulmonary hypertension treatment protocols require hospitals to maintain detailed documentation of gas therapy administration, making advanced delivery systems essential. The concentration of leading pharmaceutical manufacturers and research institutions focused on neonatal care keeps US demand significantly ahead of other regions.
Canada's inhaled nitric oxide market benefits from universal healthcare coverage that includes advanced respiratory therapies for premature infants. Canadian hospitals increasingly adopt US-approved delivery devices due to regulatory alignment and proximity to American suppliers. Growing awareness of bronchopulmonary dysplasia prevention in neonatal intensive care units is pushing provincial health authorities to formalize treatment protocols that previously relied on informal practices.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe reached USD 0.28 billion in 2025, holding 27.4% market share, and is projected to grow at 7.18% CAGR. EMA oversight and national health technology assessment requirements mean European hospitals must justify inhaled nitric oxide use through documented clinical outcomes, making catalog-style treatment tracking less optional and more of a reimbursement prerequisite.
German hospitals operate under strict Medizinproduktegesetz (Medical Devices Act) requirements, meaning inhaled nitric oxide systems must carry CE marking and undergo rigorous post-market surveillance. Hospital pharmacy committees and clinical governance boards typically approve which delivery platforms can be used, so German deployments emphasize documented approval trails and traceability from procurement to patient administration more deliberately than elsewhere.
Post-Brexit divergence from EU medical device regulations has created separate UKCA marking requirements, adding compliance complexity for manufacturers. London's concentration of specialist neonatal centers and respiratory research hospitals reinforces demand from both clinical excellence and regulatory directions, with NHS procurement frameworks adding another layer of documentation requirements.
Asia Pacific was valued at USD 0.23 billion in 2025, with a 21.8% market share, and is expected to grow at 9.34% CAGR—the highest among all regions. Many healthcare systems here are building inhaled nitric oxide therapy protocols from an earlier stage compared to North America or Europe, creating substantial growth potential.
China's National Medical Products Administration (NMPA) requires inhaled nitric oxide devices to meet domestic registration standards, meaning multinational companies often need China-specific product approvals rather than relying on global certifications. Data localization and medical device traceability laws require certain treatment records to stay within the country, driving demand for localized delivery and monitoring systems.
Japan's aging population and advanced neonatal care infrastructure create steady demand, though many hospitals still use older gas delivery systems that are harder to integrate with modern electronic health records. Much of the current market activity focuses on upgrading legacy equipment to meet newer safety standards and enable better treatment documentation, not just adding new therapy capacity.
The region reached USD 0.04 billion in 2025, representing 3.5% market share, and is projected to grow at 7.29% CAGR. Government-funded healthcare programs and medical tourism initiatives in Gulf states account for a larger share of inhaled nitric oxide spending here than private enterprise budgets.
Smart-healthcare initiatives in Dubai and Abu Dhabi route most large medical equipment procurement through public-sector hospital groups, which means government healthcare standards and centralized procurement cycles, not individual hospital budgets, set the pace of inhaled nitric oxide system adoption.
The private hospital sector's push to achieve international accreditation standards, combined with public health initiatives around maternal and child health, is driving inhaled nitric oxide adoption from both quality-improvement and regulatory compliance directions rather than a single trigger.
Competition centers on therapeutic gas reliability, portable delivery systems, hospital contracts, clinical support, and cylinder-free technology. Mallinckrodt’s INOmax remains an established brand, while VERO Biotech’s GENOSYL and Beyond Air’s LungFit PH compete through tankless or point-of-care delivery models. Air Liquide, Linde, BOC Healthcare, and other medical-gas companies benefit from established production and distribution networks. Device differentiation is increasingly important because hospitals want easier transport, reduced storage, automated monitoring, dependable backups, and lower operational burden. Pricing pressure is visible as alternative platforms gain placements, forcing suppliers to strengthen service agreements, purchasing-group access, international distribution, and next-generation equipment.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Head
Ismail Sutaria is a market intelligence and strategy professional with over 12 years of experience advising organizations across the chemicals, packaging, industrial machinery, and energy & power sectors. He specializes in delivering data-driven market assessments, commercial due diligence, industry benchmarking, demand forecasting, competitive strategy, and growth advisory that enable businesses to make confident investment and expansion decisions in complex industrial markets.
His expertise spans specialty and commodity chemicals, advanced and sustainable packaging solutions, industrial automation, manufacturing equipment, process engineering, renewable energy, conventional power generation, electrical infrastructure, and industrial technologies. Ismail has developed deep domain knowledge in evaluating market ecosystems, technology evolution, regulatory frameworks, supply-demand dynamics, pricing trends, value chain structures, and competitive landscapes across global and regional markets.
Refrigerants Market Size, Share, Growth, Analysis, Report, 2034
Argon Gas Market Size, Share, Growth, Analysis, Report, 2034
Green Ammonia Market Size, Share, Growth, Analysis, Report, 2034
Biomethane Market Size, Share, Growth, Analysis, Report, 2034
Green Hydrogen Market Size, Share, Growth, Analysis, 2034
Carbon Monoxide Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com